Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature

CONCLUSION: The study showed that a subgroup of patients with a clinical high risk and a genomic low risk ER+/HER2-breast cancer benefits from NET resulting in BCS instead of a mastectomy. Additionally, NET may enable de-escalation in axillary treatment.PMID:38599047 | DOI:10.1016/j.breast.2024.103726

Source: Breast - April 10, 2024 Category: Cancer & Oncology Authors: Josefien P van Olmen Chaja F Jacobs Sanne A L Bartels Claudette E Loo Joyce Sanders Marie-Jeanne T F D Vrancken Peeters Caroline A Drukker Frederieke H van Duijnhoven Marleen Kok Source Type: research